about us

With the global benefits of the new science of nanomedicine growing each year, the British Society for Nanomedicine has been created to allow open access for industry, academia, clinicians and the public to news and details of ongoing research throughout the UK.

As a registered charity (Charity number 1151497) our mission includes the direct explanation of the ongoing science and commercial developments to allow the public to understand and stay in touch with this exciting area as it impacts future global healthcare. Scientists can also present their latest advances and highlight their work to industry and other researchers.

The Society is affiliated to other leading organisations involved with nanomedicine including :  CLINAM, the European Technology Platform for Nanomedicine, the British Pharmacological Society and the American Society for Nanomedicine. For these and other important partnerships see our Links page.

You are welcome to join the Society through our membership page and we would be happy to hear your comments and about ways in which you want to be involved with the BSNM.

We would also like to acknowledge initial funding to create the Society from the Engineering and Physical Sciences Research Council

Steve Conlan FRSB is Professor of Molecular and Cell Biology, Swansea University Medical School, with over 25 years of experience in biomedical research and higher education. Steve is involved in the leadership of several organisations; Chair of the Board of Trustees of the British Society of Nanomedicine, and Co-Vice Chair of the European Technology Platform – Nanomedicine. He is programme board member, and research and innovation group chair, for two national precision medicine initiatives; Advanced Therapies Wales and Genome Partnerships Wales. His university research focuses on the development of advanced therapeutics; Antibody Drug Conjugates, exosomes, and nanoparticle deliver systems, and understanding disease processes using functional genomics approaches.

Maya Thanou is a professor of Pharmaceutical Nanotechnology at the Institute of Pharmaceutical Science, at the School of Cancer and Pharmaceutical Sciences, at King’s College London. Maya has over 20 years of experience in nanomedicine, she has authored over 120 scientific articles and chapters and is a co-inventor on 10 patents/patent applications. Maya is the CEO of a King’s College London spinout Apeikon Therapeutics. Apeikon’s technology aims to make novel solutions for hard-to-treat tumors. Her research focuses on activatable drug delivery systems using imaging and non-invasive interventions such as focused ultrasound.

“Hello, and a very warm welcome to the British Society of Nanomedicine. We are honoured to be appointed as the Co-Chairs of the Board of Trustees of BSNM and would like to take this opportunity to thank Andrew Owen and Steve Rannard for all of their hard work, commitment and leadership over the last 10 years!

We are delighted that Andrew and Steve will remain active in the Society moving forward.

One of our first actions as Chairs is to host a series of early career researcher events building on the success of the annual events that have been held around the UK over the past 10 years. The first of these will take place online on November 25^th and 26^th and will provide an opportunity for early career researchers to showcase innovative research and discuss outputs and opportunities with other researchers and experts in the field of nanomedicine (click here for more information and registration). We and all the other BSNM Trustees look forward to seeing you there.

Another new development is the partnership we are setting up with the journal of Precision Nanomedicine (PRNANO). This new journal is also sponsored by CLINAM and endorsed by the European Society for Nanomedicine. We look forward to working with PRNANO over the coming years. Details of the journal will appear on the website soon.

We look forward to working with you our members in the coming months as we continue to promote and share research ideas and enable collaborations that will benefit the nanomedicine community in UK and beyond.”